Interleukin 24 in Epidermal Function
白细胞介素 24 对表皮功能的影响
基本信息
- 批准号:7229781
- 负责人:
- 金额:$ 22.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-03-09 至 2008-12-31
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelAnti-Inflammatory AgentsAnti-inflammatoryAreaB-LymphocytesBindingBiological ModelsBiological ProcessCell ProliferationCellsChronicComplexConditionCutaneousCytokine ActivationCytokine Network PathwayCytokine SignalingDefectDermalDrug or chemical Tissue DistributionEpidermisExcisionExhibitsFamilyGrowth FactorHematopoieticHumanInflammatory ResponseInjuryInterleukin-1Interleukin-10Interleukin-24Interleukin-3Knockout MiceLigandsModelingMononuclearMusNumbersPhysiologicalPlayProcessProductionRecruitment ActivityResearchResearch PersonnelRoleSignal PathwaySignal TransductionSiteSkinSourceTestingTissuesWound Healingattenuationcytokinekeratinocytemacrophagemembermigrationmonocyteparacrineprogramsreceptorreceptor expressionresponsewound
项目摘要
DESCRIPTION (provided by applicant): The overall objective of this R21 research plan is to uncover the physiological functions of IL-24, a new cytokine that we recently discovered. IL-24 belongs to the IL-10 family of cytokines. We have identified two heterodimeric EL-24 receptors (IL-22R1/IL-20R2 and IL-20R1 and IL-20R2) which when bound to the ligand leads to STATs activation. Tissue distribution analysis of IL-24 receptor expression indicates that epidermis is one of the major IL-24 target tissues, in contrast to IL-10, which acts mainly on cells from hemopoeitic lineage. We showed that keratinocyres not only expresses IL-24 receptors but also can be activated by IL-24, which leads to mainly StatS activation. Consistently, stat 3 knockout mice were shown to exhibit defects in wound healing. Furthermore, IL-24 expression was found greatly increased during cutaneous wound healing process, and infiltrating mononuclear cells congregating right beneath the wounded epidermis were shown to be the source of IL-24 production. Logically, here we have selected the wound healing process as a model system to explore the physiological functions of IL-24 signaling. We hypothesize that IL-24 may be an important regulator for at least three keratinocyte functions. First, IL-24 produced by infiltrating monocytes may function, in an analogous manner to IL-10 on hematopoietic cells, to inhibit the synthesis of proinflammatory cytokines such as IL-1 and TNF-a by epidermis. In this regard, IL-24 may function as an anti-inflammatory cytokine that signals the attenuation or ultimate termination of inflammatory responses in the skin during the wound healing process. Secondly, IL-24 may function as a signal for keratinocyte proliferation, migration and differentiation during tissue repair. This hypothesis is supported by our finding that IL-24 could substitute IL-3 as a survival and growth factor for murine IL-3 dependent pro-B cells in IL-24 receptor-dependent manner. Thirdly, IL-24 may be part of a more complex cytokine network involved in the wound healing process. We propose the following specific aims to test these hypothesis: Specific Aim 1: To determine the biological functions of IL-24 on keratinocytes by testing if IL-24 can inhibit the production of proinflammatory cytokines, and promote cell proliferation, migration and differentiation. Specific Aim 2: To determine the role of IL-24 in wound healing using mouse skin excision wound model and IL-24 antagonists.
描述(由申请人提供):该R21研究计划的总体目标是揭示IL-24的生理功能,IL-24是我们最近发现的一种新细胞因子。IL-24属于细胞因子的IL-10家族。我们已经鉴定了两种异源二聚体EL-24受体(IL-22 R1/IL-20 R2和IL-20 R1和IL-20 R2),其在与配体结合时导致STAT活化。IL-24受体表达的组织分布分析表明,表皮是IL-24的主要靶组织之一,而IL-10主要作用于造血谱系的细胞。我们发现角质形成细胞不仅表达IL-24受体,而且可以被IL-24激活,这主要导致StatS激活。一致地,stat 3敲除小鼠显示出伤口愈合缺陷。此外,发现IL-24表达在皮肤创伤愈合过程中大大增加,并且显示聚集在创伤表皮正下方的浸润单核细胞是IL-24产生的来源。从逻辑上讲,我们选择伤口愈合过程作为模型系统来探索IL-24信号转导的生理功能。我们推测IL-24可能是至少三种角质形成细胞功能的重要调节因子。首先,由浸润的单核细胞产生的IL-24可以以与造血细胞上的IL-10类似的方式起作用,以抑制表皮合成促炎细胞因子如IL-1和TNF-α。在这方面,IL-24可以作为抗炎细胞因子起作用,其在伤口愈合过程中发出减弱或最终终止皮肤中炎症反应的信号。其次,IL-24可能在组织修复过程中作为角质形成细胞增殖、迁移和分化的信号。我们发现IL-24可以以IL-24受体依赖的方式取代IL-3作为小鼠IL-3依赖性pro-B细胞的存活和生长因子,这一假设得到了支持。第三,IL-24可能是参与伤口愈合过程的更复杂的细胞因子网络的一部分。我们提出了以下具体目标来验证这些假设:具体目标1:通过检测IL-24是否可以抑制促炎细胞因子的产生,以及促进细胞增殖、迁移和分化,来确定IL-24对角质形成细胞的生物学功能。具体目的2:使用小鼠皮肤切除伤口模型和IL-24拮抗剂确定IL-24在伤口愈合中的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PENG LIANG其他文献
PENG LIANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PENG LIANG', 18)}}的其他基金
Trimer-Tag: A Technology for Producing Trivalent Biologics
Trimer-Tag:一种生产三价生物制剂的技术
- 批准号:
8200347 - 财政年份:2011
- 资助金额:
$ 22.92万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 22.92万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 22.92万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 22.92万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 22.92万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 22.92万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 22.92万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 22.92万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 22.92万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 22.92万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 22.92万 - 项目类别:














{{item.name}}会员




